Can P-glycoprotein expression on malignant tumor tissues predict opioid transport at the blood-brain barrier in cancer patients?

Pharmacological Reports

Volumn 65, Issue 1, 2013, Pages 235-236

  Mégarbane, Bruno ^a,b   Alhaddad, Hisham ^a  

^a INSERM   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Analgesia; Blood brain barrier; Buprenorphine; Morphine; P glycoprotein

Indexed keywords

BUPRENORPHINE; ESTROGEN RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MORPHINE; MULTIDRUG RESISTANCE PROTEIN; OPIATE DERIVATIVE; OPIATE RECEPTOR; PREGNANE X RECEPTOR; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR AP 1;

ANALGESIC ACTIVITY; BLOOD BRAIN BARRIER; CANCER PATIENT; CANCER TISSUE; DRUG TRANSPORT; HUMAN; LETTER; MALIGNANT NEOPLASTIC DISEASE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RECEPTOR UPREGULATION;

EID: 84875767549     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(13)70984-8     Document Type: Letter

References (12)

1. Albermann N, Schmitz-Winnenthal FH, Z'Graggen K, Volk C, Hoffmann MM, Haefeli WE, Weiss J: Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol, 2005, 70, 949-958.
2. Alhaddad H, Cisternino S, Declèves X, Tournier N, Schlatter J, Chiadmi F, Risède P et al.: Respiratory toxicity of buprenorphine results from the blockage of P-glycoprotein-mediated efflux of norbuprenorphine at the blood-brain barrier in mice. Crit Care Med, 2012, 40, 3215-3223
3. Becquemont L, Camus M, Eschwege V, Barbu V, Rey E, Funck-Brentano C, Jaillon P: Lymphocyte P-glycoprotein expression and activity before and after rifampicin in man. Fundam Clin Pharmacol, 2000, 14, 519-525.
4. De Moerloose B, Dhooge C, Philippe J: Discordance of P-glycoprotein expression and function in acute leukemia. Adv Exp Med Biol, 1999, 457, 107-118.
5. Hassan HE, Myers AL, Coop A, Eddington ND: Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation. J Pharm Sci, 2009, 98, 4928-4940.
6. Miller DS: Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol Sci, 2010, 31, 246-254.
7. Nekhayeva IA, Nanovskaya TN, Hankins GD: Role of human placental efflux transporter P-glycoprotein in the transfer of buprenorphine, levo-alpha-acetylmethadol, and paclitaxel. Am J Perinatol, 2006, 23, 423-430.
8. Suzuki T, Zaima C, Moriki Y, Fukami T, Tomono K: P-glycoprotein mediates brain-to-blood efflux transport of buprenorphine across the blood-brain barrier. J Drug Target, 2007, 15, 67-74.
9. Tournier N, Declèves X, Saubaméa B, Scherrmann JM, Cisternino S: Opioid transport by ATP-binding cassette transporters at the blood-brain barrier: implications for neuropsychopharmacology. Curr Pharm Des, 2011, 17, 2829-2842.
10. Tournier N, Chevillard L, Megarbane B, Pirnay S, Scherrmann JM, Declèves X: Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol, 2010, 13, 905-915.
11. von Richter O, Burk O, Fromm MF, Thon KP, EichelbaumM, Kivisto KT: Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther, 2004, 75, 172-183.
12. Wang J, Cai B, Huang DX, Yang SD, Guo L: Decreased analgesic effect of morphine, but not buprenorphine, in patients with advanced P-glycoprotein+ cancers. Pharmacol Rep, 2012, 64, 870-877.